| |
Plasma
|
Urine
|
Saliva
|
|---|
|
Markers
|
AN
|
CTRL
|
pBonf
|
AN
|
CTRL
|
pBonf
|
AN
|
CTRL
|
pBonf
|
|
TBARS
|
5.74 (3.47–10.82)
|
3.88 (3.15–6.48)
|
NS
|
1.60 (0.38–6.73)
|
1.16 (0.28–1.45)
|
NS
|
0.48 (0.22–0.90)
|
0.11 (0.08–0.13)
|
<0.0001
|
|
μmol/l
| |
μmol/mmol creatinine
| |
μmol/l
| |
|
AOPP
|
0.84 (0.54–1.26)
|
0.33 (0.23–0.84)
|
<0.0001
|
48.4 (25.7–81.3)
|
12.0 (9.8–16.6)
|
<0.0002
|
8.20 (2.8–23.4)
|
24.5 (6.1–34.9)
|
NS
|
|
μmol/g proteins
| |
μmol/mmol creatinine
| |
μmol/l
| |
|
AGEs
|
0.030 (0.020–0.040)
|
0.023 (0.018–0.024)
|
<0.0001
|
ND
|
ND
| |
0.47 (0.28–0.82
|
0.31 (0.16–0.43
|
<0.0071
|
|
g/g proteins
| |
g/mmol creatinine
| |
g/l
| |
|
FRUCTOS
|
1.85 (1.39–2.20)
|
1.36 (1.24–1.97)
|
NS
|
0.72 (0.52–1.03)
|
0.48 (0.37–0.54)
|
.<0.0083
|
0.21 (0.14–0.39)
|
0.09 (0.04–0.30)
|
NS
|
|
mmol/l
| |
mmol/mmol creatinine
| |
mmol/l
| |
|
FRAP
|
592 ± 129
|
600 ± 153
|
NS
|
1555 (613–5309)
|
552 (395–819)
|
<0.0002
|
131 (66–267)
|
143 (105–161)
|
NS
|
|
μmol/l
| |
μmol/mmol creatinine
| |
μmol/l
| |
|
TAC
|
393 (235–674)
|
879 (502–1164)
|
<0.0001
|
1652 (699–4533)
|
573 (481–958)
|
<0.0002
|
567 (260–776)
|
393 (234–541)
|
NS
|
|
μmol/l
| |
μmol/mmol creatinine
| |
μmol/l
| |
|
GSH/GSSG
|
5.46 (4.51–9.16)
|
8.99 (6.03–12.51)
|
<0.0001
|
0.81 (0.70–1.14)
|
1.32 (0.78–1.54)
|
NS
|
0.66 (0.38–1.42)
|
0.37 (0.30–0.43)
|
<0.001
|
|
ratio
| |
ratio
| |
ratio
| |
- AGEs advanced glycation end products, AN anorexia nervosa, AOPP advanced oxidation protein products, FRAP ferric reducing antioxidant power, FRUCTOS fructosamines, GSH/GSSG a ratio of reduced and oxidized glutathione, NS non-significant, TAC total antioxidant capacity, TBARS thiobarbituric acid reactive substance; Results are expressed as mean ± SD (normally distributed data) or as median (interquartile range), (skewed data)
